Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|November 27, 2012
Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD studyE I Braicu, C Fotopoulou, T Van Gorp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2012
Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activationS Bondong, H Kiefel, T Hielscher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2016
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trialF Trillsch, S Mahner, F Hilpert, et al.
Gynecologic Oncology|July 24, 2013
The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD studyG Hofstetter, N Concin, I Braicu, et al.
British Journal of Cancer|October 20, 2011
Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancerG Hofstetter, A Berger, E Schuster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 22, 2021
Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohortS Schrodi, M Braun, A Andrulat, et al.
Scientific Reports|December 19, 2023
Characterization and prognostic impact of ACTBL2-positive tumor-infiltrating leukocytes in epithelial ovarian cancerN E Topalov, D Mayr, C Kuhn, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2014
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)I Ruscito, D Dimitrova, I Vasconcelos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2016
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)J Sehouli, R Chekerov, A Reinthaller, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Safety and dose modification for patients receiving niraparibJ S Berek, U A Matulonis, U Peen, et al.
Pageof 5